Sherman Steven I
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 435, Houston, TX 77030, USA.
Endocrinol Metab Clin North Am. 2008 Jun;37(2):511-24, xi. doi: 10.1016/j.ecl.2008.02.005.
Historically, systemic therapies for advanced, metastatic thyroid carcinomas have been poorly effective. However, as a result of a confluence of increasing knowledge of the biologic basis for thyroid cancer development and progression, identification of therapeutic agents that could target these biologic abnormalities, and enthusiasm for research by both funding agencies as well as patients, multiple clinical trials have been initiated and successfully completed during the past several years. This article focuses on findings from key studies that reflect the new paradigms for treatment.
从历史上看，针对晚期转移性甲状腺癌的全身治疗效果一直不佳。然而，由于对甲状腺癌发生和发展的生物学基础的认识不断增加、能够靶向这些生物学异常的治疗药物的发现，以及资助机构和患者对研究的热情，在过去几年中启动并成功完成了多项临床试验。本文重点介绍了反映新治疗模式的关键研究结果。
